Oncogenic alterations in advanced NSCLC: a molecular super-highway
University Hospital of Geneva · Générale-Beaulieu Clinic · +4 more institutions
Abstract
Lung cancer ranks among the most common cancers world-wide and is the first cancer-related cause of death. The classification of lung cancer has evolved tremendously over the past two decades. Today, non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, comprises a multitude of molecular oncogenic subsets that change both the prognosis and management of disease.Since the first targeted oncogenic alteration identified in 2004, with the epidermal growth factor receptor (EGFR), there has been unprecedented progress in identifying and targeting new molecular alterations. Almost two decades of experience have allowed scientists to elucidate the biological function of oncogenic drivers and understand…
Citation impact
- FWCI
- 41.71
- Percentile
- 100%
- References
- 290
Authors
5Topics & keywords
- ROS1
- KRAS
- Anaplastic lymphoma kinase
- Cancer research
- Crizotinib
- Epidermal growth factor receptor
- Lung cancer
- Medicine
- Good health and well-being